About Structure Therapeutics Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://structuretx.com/
Frequently Asked Questions
What is the 52-week range for GPCR?
The 52-week high is $94.9 and the 52-week low is $25.5901.
What is the P/E ratio for GPCR?
The P/E ratio data is currently unavailable.
What is the dividend yield for GPCR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -16.89%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.71.
Analyst Recommendation Trends
Wall Street analyst consensus for GPCR over the last few months:
Latest GPCR News
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.
Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus
Structure Therapeutics (GPCR) has put fresh clinical data for its oral obesity pipeline in front of investors, highlighting results from early stage ACCG-2671 studies and longer term aleniglipron weight loss trials. Recent trading tells a mixed story for Structure Therapeutics. The 1-day share price return of 5.17% to US$36.81 came after a year-to-date share price decline of 45.96%. Meanwhile, the 1-year total shareholder return of 50.55% points to strong longer term momentum that has cooled...
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Structure Therapeutics Inc. (GPCR) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 10:45 AM EDTCompany ParticipantsRaymond...
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?
Structure Therapeutics Inc. (NASDAQ:GPCR) reported September 8 results for ACCG-2671, an oral dual amylin and calcitonin receptor agonist. The single-dose portion of a Phase 1/2a trial enrolled 31 healthy adults without obesity. Six participants receiving 10 milligrams recorded a mean 3.3% body-weight reduction at day 24. For investors, the attraction is measurable activity after one […]
Structure Therapeutics: The Amylin Data Changes The Math
Structure Therapeutics (GPCR) outlook: aleniglipron obesity data de-risks lead asset, amylin adds upside, cash strongâsee risks & catalysts; read now.
Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target
Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management...
Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial
Structure Therapeutics (GPCR) said Tuesday that a single dose of its ACCG-2671 drug candidate reduce
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data
Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron.
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027 Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no ob
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September: 2026 Cantor Global Healthcare ConferenceDate: Thursday, September 10Format: Fireside chat and 1x1 meetingsTime: 3:55 – 4:25 PM EDTLocation: New York, NY
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-21 | Coll Crespo Blas | -4,008 | $36.1459 | $144,873 |
| 2026-09-21 | Coll Crespo Blas | +4,008 | - | - |
| 2026-09-21 | Coll Crespo Blas | -12,024 | - | - |
| 2026-09-18 | Coll Crespo Blas | -10,626 | $11.67 | $124,005 |
| 2026-09-01 | Lin Xichen | -100 | $47.83 | $4,783 |
| 2026-09-01 | Lin Xichen | -4,539 | $47.203 | $214,254 |
| 2026-09-01 | Lin Xichen | -1,300 | $45.8642 | $59,623 |
| 2026-09-01 | Lin Xichen | +5,939 | - | - |
| 2026-09-01 | Lin Xichen | -17,817 | - | - |
| 2026-09-01 | Lin Xichen | -17,817 | - | - |
| 2026-09-01 | Lin Xichen | +17,817 | $0.34 | $6,058 |
| 2026-08-18 | Lin Xichen | -400 | $55.05 | $22,020 |
| 2026-08-18 | Lin Xichen | -519 | $54.197 | $28,128 |
| 2026-08-18 | Lin Xichen | -3,020 | $53.133 | $160,462 |
| 2026-08-18 | Lin Xichen | +3,939 | - | - |
| 2026-08-18 | Lin Xichen | -11,817 | - | - |
| 2026-08-18 | Lin Xichen | -11,817 | - | - |
| 2026-08-18 | Lin Xichen | +11,817 | $0.34 | $4,018 |
| 2026-08-06 | Berrios John Joseph | +174,612 | - | - |
| 2026-08-06 | Berrios John Joseph | +140,766 | - | - |
| 2026-08-04 | Lin Xichen | -839 | $50.029 | $41,974 |
| 2026-08-04 | Lin Xichen | -3,100 | $49.2857 | $152,786 |
| 2026-08-04 | Lin Xichen | +3,939 | - | - |
| 2026-08-04 | Lin Xichen | -11,817 | - | - |
| 2026-08-04 | Lin Xichen | -11,817 | - | - |
| 2026-08-04 | Lin Xichen | +11,817 | $0.34 | $4,018 |
| 2026-07-22 | FMR LLC | -16,085 | $50.07 | $805,376 |
| 2026-07-22 | FMR LLC | -1,367 | $50.07 | $68,446 |
| 2026-07-14 | Lin Xichen | -1,600 | $51.7088 | $82,734 |
| 2026-07-14 | Lin Xichen | -6,278 | $50.7956 | $318,895 |
| 2026-07-14 | Lin Xichen | +7,878 | - | - |
| 2026-07-14 | Lin Xichen | -23,634 | - | - |
| 2026-07-14 | Lin Xichen | -23,634 | - | - |
| 2026-07-14 | Lin Xichen | +23,634 | $0.34 | $8,036 |
| 2026-06-17 | Russell Angus C. | +39,453 | - | - |
| 2026-06-17 | TETLOW SHARON | +39,453 | - | - |
| 2026-06-17 | WELCH DANIEL G | +39,453 | - | - |
| 2026-06-17 | DOBMEIER ERIC | +39,453 | - | - |
| 2026-06-17 | LOVE TED W | +39,453 | - | - |
| 2026-04-15 | Lang Matthew | +223,776 | - | - |
| 2026-04-15 | Lang Matthew | +184,614 | - | - |
| 2026-04-14 | FMR LLC | -16,085 | $55.07 | $885,801 |
| 2026-04-14 | FMR LLC | -1,367 | $55.07 | $75,281 |
| 2026-03-19 | Coll Crespo Blas | +93,984 | - | - |
| 2026-03-19 | Coll Crespo Blas | +75,897 | - | - |
| 2026-03-19 | Ma Yingli | +40,278 | - | - |
| 2026-03-19 | Ma Yingli | +32,526 | - | - |
| 2026-03-19 | Lin Xichen | +53,703 | - | - |
| 2026-03-19 | Lin Xichen | +43,368 | - | - |
| 2026-03-19 | Yoon Jun | +128,892 | - | - |
| 2026-03-19 | Yoon Jun | +104,085 | - | - |
| 2026-03-19 | Hall Ashley | +59,073 | - | - |
| 2026-03-19 | Hall Ashley | +47,706 | - | - |
| 2026-03-19 | Stevens Raymond C | +322,230 | - | - |
| 2026-03-19 | Stevens Raymond C | +260,217 | - | - |
| 2026-03-03 | Coll Crespo Blas | -11,826 | $20.99 | $248,228 |
| 2026-03-03 | Ma Yingli | -11,313 | $20.99 | $237,460 |
| 2026-03-03 | Lin Xichen | -18,735 | $20.99 | $393,248 |
| 2026-03-03 | Yoon Jun | -22,305 | $20.99 | $468,182 |
| 2026-03-03 | Hall Ashley | -4,836 | $20.99 | $101,508 |
| 2026-03-03 | Stevens Raymond C | -53,454 | $20.99 | $1,121,999 |
| 2026-01-15 | FMR LLC | -230 | $85.04 | $19,559 |
| 2026-01-15 | FMR LLC | -6,498 | $84.22 | $547,262 |
| 2026-01-15 | FMR LLC | -3,880 | $83.35 | $323,398 |
| 2026-01-15 | FMR LLC | -5,477 | $82.1 | $449,662 |
| 2026-01-15 | FMR LLC | -20 | $85.04 | $1,701 |
| 2026-01-15 | FMR LLC | -552 | $84.22 | $46,489 |
| 2026-01-15 | FMR LLC | -330 | $83.35 | $27,505 |
| 2026-01-15 | FMR LLC | -465 | $82.1 | $38,177 |
| 2025-12-08 | FMR LLC | -15,535 | $61.45 | $954,626 |
| 2025-12-08 | FMR LLC | -16,635 | $61.05 | $1,015,567 |
| 2025-12-08 | FMR LLC | -5,589 | $94.61 | $528,775 |
| 2025-12-08 | FMR LLC | -2,159 | $94 | $202,946 |
| 2025-12-08 | FMR LLC | -8,337 | $92.52 | $771,339 |
| 2025-12-08 | FMR LLC | -1,320 | $61.45 | $81,114 |
| 2025-12-08 | FMR LLC | -1,414 | $61.05 | $86,325 |
| 2025-12-08 | FMR LLC | -475 | $94.61 | $44,940 |
| 2025-12-08 | FMR LLC | -183 | $94 | $17,202 |
| 2025-12-08 | FMR LLC | -709 | $92.52 | $65,597 |
| 2025-11-20 | Hall Ashley | +237 | - | - |
| 2025-11-20 | Stevens Raymond C | +824 | - | - |